NAT-2 (4-KK21): sc-134399



The Power to Question

BACKGROUND

Arylamine N-acetyltransferases (NAT-1 and NAT-2) catalyze N- or O-acetylation of heterocyclic and arylamine substrates in the detoxification of a wide array of drugs. Certain alleles causing high levels of N-acetyltransferase activity have been associated with colon and urinary bladder cancers, as NAT's also bioactivate several known carcinogens. Both NAT-1 and NAT-2 are cytoplasmic proteins and play an active role in the detoxification of many arylamine and hydrazine drugs. N-acetylation polymorphism is determined by the level of NAT activity in liver tissues, and has been linked to the action and toxicity of drugs that contain amines.

REFERENCES

- Lanckriet, C., Bureau, J.J., Capdevielle, H., Gody, J.C., Olivier, T. and Siopathis, R.M.1992. Morbidity and mortality in the pediatric service of Banqui (Central African Republic) during the year 1990. Implications for public health. Ann. Pediatr. 39:125-130.
- Kiss, I., Nemeth, A., Bogner, B., Pajkos, G., Orsos, Z., Sandor, J., Csejtey, A., Faluhelyi, Z., Rodler, I. and Ember, I. 2004. Polymorphisms of glutathione-Stransferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer. Anticancer Res. 24: 3965-3970.
- Li, Y.C., Tyan, Y.S., Lee, Y.M., Tsao, T.Y., Chuang, J.Y., Kuo, H.M., Hsia, T.C., Yang, J.H. and Chung, J.G. 2005. N-acetyltransferase is involved in baicalein-induced N-acetylation of 2-aminofluorene and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells. *In Vivo* 19: 399-405.
- Deguchi, M., Yoshida, S., Kennedy, S., Ohara, N., Motoyama, S. and Maruo, T. 2005. Lack of association between endometriosis and N-acetyl transferase 1 (NAT-1) and 2 (NAT-2) polymorphisms in a Japanese population. J. Soc. Gynecol. Investig. 12: 208-213.
- Zhang, X.F., Bian, J.C., Zhang, X.Y., Zhang, Z.M., Jiang, F., Wang, Q.M., Wang, Q.J., Cao, Y.Y. and Tang, B.M. 2005. Are polymorphisms of Nacetyltransferase genes susceptible to primary liver cancer in Luoyang, China? World J. Gastroenterol. 11: 1457-1462.
- Broberg, K., Bjork, J., Paulsson, K., Hoglund, M. and Albin, M. 2005. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 26: 1263-1271.

CHROMOSOMAL LOCATION

Genetic locus: NAT2 (human) mapping to 8p22.

SOURCE

NAT-2 (4-KK21) is a mouse monoclonal antibody raised against recombinant NAT-2 protein of human origin.

PRODUCT

Each vial contains 100 μg IgG_{2a} kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

NAT-2 (4-KK21) is recommended for detection of NAT-2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)] and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for NAT-2 siRNA (h): sc-61156, NAT-2 shRNA Plasmid (h): sc-61156-SH and NAT-2 shRNA (h) Lentiviral Particles: sc-61156-V.


Molecular Weight of NAT-2: 34 kDa.

Positive Controls: human NAT-2 transfected 293T whole cell lysate.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml).

DATA



NAT-2 (4-KK21): sc-134399. Western blot analysis of NAT-2 expression in human NAT-2 transfected (**A**) and non-transfected (**B**) 293T whole cell Ivsates.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com